


**What is Claimed is:**

1. A compound of the formula



5 wherein

$\text{R}^1$  represents a hydrogen atom or a group selected from the formulae (A) and (B)

(A)  $\text{R}^3\text{-CO-(CH}_2\text{)}_s\text{-CO-}$ ,

in which

$\text{R}^3$  represents  $\text{R}^4\text{-Z}^1$  with  $\text{Z}^1$  being O or  $\text{NR}^5$ ,  $\text{R}^4$ ,  $\text{R}^5$  being each independently

10 hydrogen or  $\text{C}_{1-6}$  alkyl, and

s is an integer from 1 to 4;

(B)  $\text{R}^6\text{-CO-}$

in which

$\text{R}^6$  represents a  $\text{C}_{1-6}$  alkyl group, a  $\text{C}_{1-6}$  haloalkyl group or a phenyl group being  
 15 optionally substituted by one or more substituents selected from the group consisting  
 of halogen,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{C}_{1-6}$  haloalkyl,  $\text{C}_{1-6}$  haloalkoxy, amino,  $\text{C}_{1-6}$   
 alkylamino, di- $(\text{C}_{1-6}$  alkyl)-amino,  $\text{C}_{1-6}$  alkoxy carbonyl, formyl, carboxy, hydroxy,  
 cyano,  $\text{SO}_3\text{H}$  and nitro;

$\text{Xaa}^1$  each independently represent an amino acid or the N-alkylated derivative thereof, at  
 20 least one of which being N-terminally linked to  $\text{R}^1$ ;

n is 0 or an integer from 1 to 3;

Y represents a single bond, or if t is 0, a spacer group selected from  $\text{-O-}$  and  $\text{-NH-}$ ;

$\text{R}^2$  represents a hydroxy group or a group of formula (C)

(C)  $\text{-Z}^2\text{-R}^7$

25 in which

$\text{Z}^2$  represents O or  $\text{NR}^8$ ,



$\text{R}^7$  represents

(a) a  $\text{C}_{1-6}$  alkyl group being optionally substituted by one or more substituents  
 selected from the group consisting of halogen,  $\text{C}_{3-8}$ -cycloalkyl, phenyl,  $\text{C}_{1-6}$





m represents 1.

6. A compound selected from the formulae (IA) through (ID):



5



10 in which  $R^1$ ,  $R^2$ ,  $Xaa^1$ ,  $Xaa^2$ ,  $n$  and  $t$  are as defined in claim 1, and  
X represents ethyl, thiomethyl or cyclopropyl; or a pharmaceutically acceptable salt or  
solvate thereof.

7. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier or diluent.
- 5 8. A pharmaceutical composition comprising a compound according to claim 6 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 7, which further comprises an  
10 active ingredient selected from the group consisting of: atorvastatin, besipirdine, cevimeline, donepezil, eptastigmine, galantamine, glatiramer acetate, icopezil, ipidacrine, lazabemide, linopirdine, lubeluzole, memantine, metrifonate, milameline, nefiracetam, nimodipine, octreotide, rasagiline, rivastigmine, sabcomeline, sabeluzole, tacrine, valproate sodium, velnacrine, YM 796, Phenserine and zanapezil.
- 15 10. A pharmaceutical composition according to claim 7, which further comprises an antiinflammatory agent selected from the group consisting of: rofecoxib, celecoxib, valdecoxib, nitroflurbiprofen, IQ-201, NCX-2216, CPI-1189, Colostrinin, ibuprofen, indomethacin, meloxicam, sulindac sulphide.
- 20 11. A pharmaceutical composition according to claim 9, which further comprises an antiinflammatory agent selected from the group consisting of: rofecoxib, celecoxib, valdecoxib, nitroflurbiprofen, IQ-201, NCX-2216, CPI-1189, Colostrinin, ibuprofen, indomethacin, meloxicam, sulindac sulphide.
- 25 12. A pharmaceutical composition according to claim 7, which further comprises a nerve growth factor or a nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, leteprinim, MCC-257, NS-521, and xaliproden.
- 30 13. A pharmaceutical composition according to claim 9, which further comprises a nerve growth factor or a nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, leteprinim, MCC-257, NS-521, and xaliproden.

14. A pharmaceutical composition according to claim 11, which further comprises a nerve growth factor or nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, leteprenim, MCC-257, NS-521, and xaliproden.

5 15. A method of treating or preventing a disease or condition in a patient, comprising administering the compound according to claim 1, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Down's syndrome, MCI ("Mild Cognitive Impairment"), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, Cerebral Amyloid Angiopathy, Traumatic Brain injury, Stroke, Dementia,  
10 Parkinson's Disease and Parkinson's Syndrome, and central or peripheral amyloid diseases.

16. A method of treating or preventing a disease or condition in a patient, comprising administering the pharmaceutical composition according to claim 7, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Down's syndrome,  
15 MCI ("Mild Cognitive Impairment"), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, Cerebral Amyloid Angiopathy, Traumatic Brain injury, Stroke, Dementia, Parkinson's Disease and Parkinson's Syndrome, and central or peripheral amyloid diseases.

17. A method for inhibiting  $\beta$ -secretase activity, comprising exposing said  $\beta$ -secretase  
20 to an effective inhibitory amount of a compound of claim 1.

18. A method for inhibiting  $\beta$ -secretase activity, comprising exposing said  $\beta$ -secretase to an effective inhibitory amount of a compound of formula IA of claim 6.